Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3173448

O=C(COc1ccc(-c2ccccc2F)nc1)Nc1nccs1.O=C(O)C(F)(F)F

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 12/20 0.58
RAB9A P51151 12/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
TP53 P04637 3/20 0.58
HPGD P15428 3/20 0.58
THRB P10828 1/20 0.58
L3MBTL1 Q9Y468 2/20 0.56
ALOX15 P16050 1/20 0.56
ALDH1A1 P00352 4/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
MAPT P10636 1/20 0.53
NFKB1 P19838 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
PKM P14618 4/20 0.51
CDK5 Q00535 1/20 0.51
CDK5R1 Q15078 1/20 0.51
MGAM O43451 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8452054 0.94 NPC1 (0.63) NPC1RAB9ASMN1; SMN2TP53HPGD
Trifluoroacetic Acid SCHEMBL3180765 0.85 NPC1 (0.67) NPC1RAB9ASMN1; SMN2TP53HPGD
Trifluoroacetic Acid SCHEMBL3180462 0.83 NPC1 (0.47) NPC1RAB9ASMN1; SMN2TP53HPGD
Trifluoroacetic Acid SCHEMBL3182204 0.80 ALOX5AP (0.43) NPC1RAB9ATP53ALOX15ALDH1A1
SCHEMBL9003839 0.78 NPC1 (0.76) NPC1RAB9ASMN1; SMN2TP53HPGD
SCHEMBL3173464 0.77 MGAM (0.42) NPC1RAB9ASMN1; SMN2TP53HPGD
SCHEMBL8460633 0.77 NPC1 (0.52) NPC1RAB9ASMN1; SMN2TP53HPGD
SCHEMBL7470030 0.75 RAB9A (1.00) NPC1RAB9ASMN1; SMN2TP53HPGD
SCHEMBL12443640 0.73 NPC1 (1.00) NPC1RAB9ASMN1; SMN2TP53HPGD
Trifluoroacetic Acid SCHEMBL3170206 0.73 NPC1 (0.57) NPC1RAB9AL3MBTL1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188291-B2 Heteroaryl-substituted carboxamides and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-20100016337-A1 HETEROARYL-SUBSTITUTED CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2010-01-21 US disclosed
EP-2097382-A1 HETEROARYL-SUBSTITUTED CARBOXAMIDES AND USE THEREOF FOR THE STIMULATION OF THE EXPRESSION OF NO SYNTHASE Sanofi-Aventis (FR) 2009-09-09 EP disclosed
WO-2008077507-A1 HETEROARYL-SUBSTITUTED CARBOXAMIDES AND USE THEREOF FOR THE STIMULATION OF THE EXPRESSION OF NO SYNTHASE SANOFI-AVENTIS (FR) 2008-07-03 WO disclosed
EP-1939181-A1 Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase sanofi-aventis (FR) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016337-A1 HETEROARYL-SUBSTITUTED CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS TBXAS1, PTGIS, NOS2 NPC1 2911/4885RAB9A 3124/4885SMN1; SMN2 4713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.